Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era

Yu Chung Huang, Chun Yu Liu, Hsueh Ju Lu, Han Tsung Liu, Man Hsin Hung, Ying Chung Hong, Liang Tsai Hsiao, Jyh Pyng Gau, Jin Hwang Liu, Hui Chi Hsu, Tzeon Jye Chiou, Po Min Chen, Cheng Hwai Tzeng, Yuan Bin Yu

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


Several revisions of International Prognostic Index (IPI) have been proposed for patients with diffuse large B-cell lymphoma (DLBCL) after the introduction of rituximab. Expanding evidence suggests that baseline absolute lymphocyte count (ALC) is also an independent factor for outcome prediction. We investigated the optimal prognostic model for these patients in the rituximab era. The study enrolled 274 consecutive patients with DLBCL receiving first-line cyclophosphamide, doxorubicin, vincristine, and prednisone based chemotherapy with rituximab between 2003 and 2009. Five factors within IPI and ALC were entered for Cox regression analysis. Overall survival (OS) and progression-free survival were calculated for different risk groups of models. Efficacy of models was compared by the value of Akaike information criterion (AIC). Revised IPI (R-IPI) and ALC/R-IPI, but not IPI, were informative to discriminate between different risk groups. In multivariate analysis for individual factors of the prognostic models, performance status >1 [odds ratio (OR) 3.59], Ann Arbor stage III or IV (OR 2.24), and ALC <1 × 109/L (OR, 2.75) remained significant. Another modified score based on the three factors divided patients into four risk groups and the 3-year OS rate was 93, 77, 39, and 13 %, respectively. By comparing AIC values in the Cox proportional hazards model, the modified three-factor model was the superior prognostic model followed by established ALC/R-IPI, R-IPI, and standard IPI. In conclusion, the addition of the novel factor, ALC, interacts with other established factors in outcome prediction for DLBCL. Development of a new score is needed for a better risk stratification in the rituximab era and would be helpful in the design of future clinical trials. The proposed three-factor model should be validated in large-scale studies.

Original languageEnglish
Pages (from-to)1513-1520
Number of pages8
JournalAnnals of Hematology
Issue number11
Publication statusPublished - Nov 2013
Externally publishedYes


  • Absolute lymphocyte count
  • Diffuse large B-cell lymphoma
  • International Prognostic Index
  • Rituximab

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era'. Together they form a unique fingerprint.

Cite this